CN107412221A - A kind of tree peony seed extract and its application as antineoplastic - Google Patents
A kind of tree peony seed extract and its application as antineoplastic Download PDFInfo
- Publication number
- CN107412221A CN107412221A CN201710658187.8A CN201710658187A CN107412221A CN 107412221 A CN107412221 A CN 107412221A CN 201710658187 A CN201710658187 A CN 201710658187A CN 107412221 A CN107412221 A CN 107412221A
- Authority
- CN
- China
- Prior art keywords
- content
- trans
- resveratrol
- tree peony
- peony seed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/004—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by obtaining phenols from plant material or from animal material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/205—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings
- C07C39/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic parts with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/40—Separation, e.g. from natural material; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Abstract
A kind of application the present invention relates to tree peony seed extract and its as antineoplastic, described tree peony seed extract, includes following composition：Trimerization Stilbene A contents are 0.3% 0.5%,Trimerization Stilbene B content is 1.0% 1.2%,Trans ε Portugals root cellulose content is 1.2% 1.5%,Four poly- Stilbene E contents are 1.2% 1.5%,Trans-resveratrol content is 0.1% 0.3%,Trans-resveratrol 4'O β D glycosides content is 0.02% 0.05%,Content of paeoniflorin is 0.2% 0.4%,Content of luteolin is 0.05% 0.1%,Cyanidenon 4'O β D glycosides content is 0.2% 0.4%,Quantitative Determination of Apigenin is 0.2% 0.3%,Kaempferol content is 0.2% 0.4%,Content of oleanolic acid is 0.1% 0.3%,TLC Determination of Betulinic Acid is 0.2% 0.4%,Hederagenin content is 0.3% 0.5%,Coffee acid content is 0.5% 0.8%.Described tree peony seed extract can be used for preventing and/or treating tumor disease.
Description
Technical field
The invention belongs to natural medicine field, and in particular to a kind of tree peony seed extract and its answering as antineoplastic
With.
Background technology
Tree peony (Paeonia suffruticosa Andr.) is Paeoniaceae, Chinese herbaceous peony platymiscium, for the perennial small filling of fallen leaves
Wood.Stem is up to 2 meters, and branch is short and thick.Terminal leaflet width egg shape, long 7-8 centimetres, wide 5.5-7 centimetres, surface green；Petiolule
It is long 1.2-3 centimetres；Side life leaflet is narrow avette or long round shape is avette, long 4.5-6.5 centimetres, wide 2.5-4 centimetres；Petiole is long 5-11 lis
Rice, and rachis are hairless.It is peony various colors, elegant and poised, the good reputation of " king in spending, aromatic " is known as, is original
The ornamental flower of Chinese Famous.Tree peony is distributed mainly in the Yellow River, Lower Reaches, including Henan, Shandong, Hebei, Shanxi etc. save.
Distribution center is in Heze City, Shandong Province, Luoyang, henan and Beijing.Its root skin, the root bark of tree peony as conventional Chinese medicine, have calm, cooling, it is antipyretic,
Analgesia, spasmolysis and other effects.《Compendium of Materia Medica》Record nourishing Yin and falling fire, solution spot poison, throat, diuresis stasis.It is conventionally used to blood
Stagnant Amenorrhea, dysmenorrhoea, carbuncle sore tumefacting virus, the pain of injury caused by falling and tumbling, beriberoid pyretic arthralgia.Modern pharmacology research show the root bark of tree peony have anticonvulsion, antibacterial,
Antiatherosclerosis, diuresis, antiulcer etc. act on.
Except root skin can make it is medicinal in addition to, tree peony whole body is precious, and its flower, pod, seed and leaf can be used as medicine.Peony seeds are in granular form,
It is wrapped in inside tree peony angle.Tree peony angle is in Five-pointed star, and angle has hard shell to protect peony seeds.Peony seeds have antioxygen
The effect of change, antibacterial, anti-inflammatory, analgesic, conventional peony seeds among the people cure the diseases such as lumbocrural pain.Peony seed oil is containing abundant α-Asia
Numb acid (＞ 40%) and omega-3 unsaturated fatty acid, have very important health care and medical value.
Composition and its conduct of a kind of peony seed total stilbene compounds as well are disclosed in Chinese patent 201310434769.X
The application of antibacterials；Chinese patent 201310218325.2 discloses a kind of Paeonia suffruticosa seed shell extract and its antibacterial, resists and swell
Tumor activity；Inventor is in periodical (Chemical Research in Chinese Universities, Volume 33, Issue
4, pp 546-551) finger-print and the quantitative analysis method of a kind of tree peony seed extract based on HPLC are described in.This hair
The bright pharmaceutical composition that the peony seeds source that a kind of active ingredient forms and content is different from above-mentioned prior art is provided, the medicine
Composition has the antitumor activity better than its single one or several components mixing.
The content of the invention
The present invention provides a kind of pharmaceutical composition, it is characterised in that described pharmaceutical composition, which includes treatment and/or prevention, to be had
Suffruticosol A (trimerization Stilbene A), suffruticosol B (trimerization Stilbene B), the trans- ε-viniferin of effect amount are (anti-
Formula ε-Portugal's root element), ampelopsin E (four poly- Stilbene E), trans-resveratrol (trans-resveratrol), trans-
Resveratrol-4'-O- β-D-glucopyranoside (trans-resveratrol -4'-O- β-D-Glucose glucoside),
Paeoniflorin (Paeoniflorin), luteolin (cyanidenon), luteolin-4'-O- β-D-glucopyranoside (wood
The plain 4'-O- β-D-Glucose glucoside of rhinoceros grass), apiolin, Kaempferol, oleanolic acid, betulic acid, hederagenin, caffeic acid
As active ingredient.It is (such as pharmaceutically acceptable that the pharmaceutical composition also includes appropriate pharmaceutically acceptable pharmaceutic adjuvant
Carrier, diluent or excipient).
In aforementioned pharmaceutical compositions, by mass percentage, active ingredient preferably comprises suffruticosol A (trimerizations
Stilbene A) content is 0.3%-0.5%, suffruticosol B (trimerization Stilbene B) content be 1.0%-1.2%, trans- ε-
Viniferin (trans ε-Portugal's root element) content is 1.2%-1.5%, ampelopsin E (four poly- Stilbene E) content is 1.2%-
1.5%th, trans-resveratrol (trans-resveratrol) content is 0.1%-0.3%, trans-resveratrol-4'-
O- β-D-glucopyranoside (trans-resveratrol -4'-O- β-D-Glucose glucoside) content be 0.02%-0.05%,
Paeoniflorin (Paeoniflorin) content be 0.2%-0.4%, luteolin (cyanidenon) content be 0.05%-0.1%,
Luteolin-4'-O- β-D-glucopyranoside (cyanidenon 4'-O- β-D-Glucose glucoside) content is 0.2%-
0.4%th, Quantitative Determination of Apigenin 0.2%-0.3%, Kaempferol content be 0.2%-0.4%, content of oleanolic acid 0.1%-
0.3%th, TLC Determination of Betulinic Acid 0.2%-0.4%, hederagenin content be 0.3%-0.5%, coffee acid content be
0.5%-0.8%.
Another embodiment of the present invention provides a kind of tree peony seed extract, it is characterised in that the tree peony seed extract
Preparation method, comprise the following steps：
(1) tree peony seed raw material is taken, crushes, obtains pulvis；
(2) pulvis that step (1) obtains first uses absolute ethyl alcohol seepage pressure effects, obtains ethanol extract；Water seepage pressure effects are used again,
Obtain aqueous extract；
(3) ethanol extract and aqueous extract obtained step (2) is concentrated after merging, dried, and obtains the peony seeds
Extract.
Crushing described in step (1), preferably grinding particle size are 10-200 mesh, more preferably 40 mesh；In step (2)
The temperature of seepage pressure effects is room temperature, and the time of seepage pressure effects is 12-24 hours, and diacolation speed is that every kilogram of pulvis rate of outflow is
2~3ml/min；Step (3) described drying is selected from vacuum drying, and vacuum drying temperature is selected from room temperature to 50 DEG C, during vacuum drying
Between preferably 12-24 hours.
Above-mentioned tree peony seed extract provided by the invention, it is characterised in that it includes following composition：By mass percentage,
Suffruticosol A (trimerization Stilbene A) content is 0.3%-0.5%, suffruticosol B (trimerization Stilbene B) content is
1.0%-1.2%, trans- ε-viniferin (trans ε-Portugal's root element) content are 1.2%-1.5%, ampelopsin E (four
Poly- Stilbene E) content be 1.2%-1.5%, trans-resveratrol (trans-resveratrol) content be 0.1%-0.3%,
Trans-resveratrol-4'-O- β-D-glucopyranoside (trans-resveratrol -4'-O- β-D-Glucose glucoside) contain
It is that 0.2%-0.4%, luteolin (cyanidenon) contain to measure as 0.02%-0.05%, paeoniflorin (Paeoniflorin) content
Measure as 0.05%-0.1%, luteolin-4'-O- β-D-glucopyranoside (cyanidenon 4'-O- β-D-Glucose glucoside)
Content is 0.2%-0.4%, Quantitative Determination of Apigenin 0.2%-0.3%, Kaempferol content are 0.2%-0.4%, oleanolic acid contains
Measure as 0.1%-0.3%, TLC Determination of Betulinic Acid 0.2%-0.4%, hederagenin content are 0.3%-0.5%, coffee
Acid content is 0.5%-0.8%.
Component content determines through HPLC in tree peony seed extract of the present invention, and HPLC chromatogram condition is：Column temperature：30℃；
Post pressure：19.11MPa；Flow velocity：1mL/min；Wavelength：230nm；Sample size：10μL；Chromatographic column：Synergi 4u Hydro-RP
80R；Column length：250×4.6mm 42μm；Mobile phase A：0.2% phosphate aqueous solution, Mobile phase B：Acetonitrile；Gradient elution program is：
0min：A is 95%, B 5%, 5min：A is 75%, B 25%, 20min：A is 45%, B 55%, 30min：A is 25%,
B is 75%, 33min：A is 0%, B 100%, 36min：A is 95%, B 5%.
Another embodiment of the present invention provides the preparation method of tree peony seed extract of the present invention, it is characterised in that bag
Include following steps：
(1) tree peony seed raw material is taken, crushes, obtains pulvis；
(2) pulvis that step (1) obtains first uses absolute ethyl alcohol seepage pressure effects, obtains ethanol extract；Water seepage pressure effects are used again,
Obtain aqueous extract；
(3) ethanol extract and aqueous extract obtained step (2) is concentrated after merging, dried, and obtains the peony seeds
Extract.
Crushing described in step (1), preferably grinding particle size are 10-200 mesh, more preferably 40 mesh；In step (2)
The temperature of seepage pressure effects is room temperature, and the time of seepage pressure effects is 12-24 hours, and diacolation speed is that every kilogram of pulvis rate of outflow is
2~3ml/min；Step (3) described drying is selected from vacuum drying, and vacuum drying temperature is selected from room temperature to 50 DEG C, during vacuum drying
Between preferably 12-24 hours.
Another embodiment of the present invention provides aforementioned pharmaceutical compositions, tree peony seed extract as prevention and/or treatment
The application of tumor disease, the preferred colorectal cancer of the tumor disease, colon cancer, liver cancer, stomach cancer, acute promyelocytic leukemic.
Another embodiment of the present invention provides aforementioned pharmaceutical compositions, tree peony seed extract is preparing prevention and/or treatment
Application in tumor disease medicine, the preferred colorectal cancer of the tumor disease, colon cancer, liver cancer, stomach cancer, acute promyelocytic leukemic.
In pharmaceutical composition of the present invention suffruticosol A (trimerization Stilbene A) include suffruticosol A with
And pharmaceutically acceptable salt, suffruticosol B (trimerization Stilbene B) include suffruticosol to suffruticosol A
Pharmaceutically acceptable salt, trans- ε-viniferin (trans ε-Portugal's root element) include B and suffruticosol B
Trans- ε-viniferin and trans- ε-viniferin pharmaceutically acceptable salt, ampelopsin E (four poly- Stilbene
E ampelopsin E and ampelopsin E pharmaceutically acceptable salt) are included, trans-resveratrol is (trans white
Veratryl alcohol) include trans-resveratrol and trans-resveratrol pharmaceutically acceptable salt, trans-
Resveratrol-4'-O- β-D-glucopyranoside (trans-resveratrol -4'-O- β-D-Glucose glucoside) include
Trans-resveratrol-4'-O- β-D-glucopyranoside and trans-resveratrol-4'-O- β-D-
Glucopyranoside pharmaceutically acceptable salt, paeoniflorin (Paeoniflorin) include paeoniflorin and
Pharmaceutically acceptable salt, luteolin (cyanidenon) include luteolin and luteolin in medicine to paeoniflorin
Acceptable salt on, luteolin-4'-O- β-D-glucopyranoside (cyanidenon 4'-O- β-D-Glucose glucoside) bags
Luteolin-4'-O- β-D-glucopyranoside and luteolin-4'-O- β-D-glucopyranoside are included in medicine
Acceptable salt on, apiolin includes apiolin and apiolin, and pharmaceutically acceptable salt, Kaempferol include Kaempferol
And pharmaceutically acceptable salt, oleanolic acid are pharmaceutically acceptable including oleanolic acid and oleanolic acid for Kaempferol
Salt, betulic acid includes betulic acid and betulic acid, and pharmaceutically acceptable salt, hederagenin include ivy
Pharmaceutically acceptable salt, caffeic acid pharmaceutically may be used including caffeic acid and caffeic acid for sapogenin and hederagenin
The salt of receiving.
When being related to seepage pressure effects in peony seeds method for preparing extractive of the present invention, its Extraction solvent used (absolute ethyl alcohol,
Water) dosage to remain that Extraction solvent (absolute ethyl alcohol, water) liquid level is higher than pulvis (medicinal material in percolator).
Compared with prior art, the advantage of the invention is that：(1) pharmaceutical composition provided by the invention and peony seeds carry
Take thing relative to prior art (such as in Chinese patent 201310434769.X embodiment 1-3 prepare the total stilbene class of peony seeds
The composition of compound；The Paeonia suffruticosa seed shell extract that in Chinese patent 201310218325.2 prepared by embodiment 2；Document
Prepared in Chemical Research in Chinese Universities, Volume 33, Issue 4, pp 546-551
Tree peony seed extract) antitumor activity significantly increases；(2) relative to list, one or several have pharmaceutical composition provided by the invention
The antitumor activity of the composition of effect composition composition significantly increases；(3) preparation method of the present invention is easy, larger without using toxicity
Acetone, methanol equal solvent, without using the means of purification such as chromatographic isolation.
Brief description of the drawings
The structural formula of 15 compounds separated in Fig. 1 tree peony seed extracts of the present invention.
The HPLC spectrograms of tree peony seed extract and reference substance mixed liquor in Fig. 2 embodiment of the present invention 1.
Embodiment
For the ease of a further understanding of the present invention, examples provided below has done more detailed description to it.But
It is that these embodiments only are not used for limiting the scope of the present invention or implementation principle, reality of the invention for being better understood from inventing
The mode of applying is not limited to herein below.
Embodiment 1
(1) tree peony seed raw material (5kg) is taken, 40 mesh is crushed to, obtains pulvis；
(2) pulvis that step (1) obtains, first with absolute ethyl alcohol seepage pressure effects, ethanol extract (7.2L) is obtained；Oozed again with water
Filter extraction, obtain aqueous extract (7.2L)；The temperature of seepage pressure effects is room temperature, and the time of seepage pressure effects is 12 hours, diacolation speed
It is 2ml/min for every kilogram of pulvis rate of outflow；
(3) ethanol extract and aqueous extract obtained step (2) concentrates after merging, vacuum drying 12 is small at 50 DEG C
When, obtain tree peony seed extract (423g, hereinafter referred to as extract A).
Above-mentioned tree peony seed extract, through the column chromatography technologies such as silica gel, CHP-20P, macroreticular resin, Sephadex LH-20 point
From obtaining 15 compounds, by nuclear magnetic resonance technique (1H NMR、l3C NMR、1H-1H COSY, DEPT, HMBC, HMQC), it is purple
The Modern spectroscopy technology such as external spectrum technology (UV), mass-spectrometric technique (MS) determines its structure, respectively suffruticosol A
(trimerization Stilbene A, 1), suffruticosol B (trimerization Stilbene B, 2), trans- ε-viniferin (trans ε-Portugal's root element, 3),
Ampelopsin E (four poly- Stilbene E, 4), trans-resveratrol (trans-resveratrol, 5), trans-resveratrol-
4'-O- β-D-glucopyranoside (trans-resveratrol -4'-O- β-D-Glucose glucoside, 6), paeoniflorin (Chinese herbaceous peonies
Glucoside, 7), luteolin (cyanidenon, 8), luteolin-4'-O- β-D-glucopyranoside (cyanidenon 4'-O- β-
D-Glucose glucoside, 9), apiolin (10), Kaempferol (11), oleanolic acid (12), betulic acid (13), hederagenin
(14), caffeic acid (15) (see accompanying drawing 1).
Using inventor in document Chemical Research in Chinese Universities, Volume 33,
Each composition in tree peony seed extract prepared by the embodiment is analyzed in quantitative analysis method disclosed in Issue 4, pp 546-551
Content.Specific method is as follows：
(98.5%) reference substance, purity are more than accurate Weigh Compound 1-15, it is dense to be configured to different quality with methanol respectively
Degree is accurate respectively to draw 10 μ L injection liquid chromatographs (as reference substance solution), by column temperature:30℃；Post pressure:19.11MPa；
Flow velocity:1mL/min；Wavelength:230nm；Sample size:10μL；Chromatographic column：Synergi 4u Hydro-RP 80R；Column length:250×
4.6mm 42μm；Mobile phase A：0.2% phosphate aqueous solution, Mobile phase B：Acetonitrile；Gradient elution program is：0min：A is 95%, B
For 5%, 5min：A is 75%, B 25%, 20min：A is 45%, B 55%, 30min：A is 25%, B 75%, 33min：
A is 0%, B 100%, 36min：A is that the chromatographic condition that 95%, B is 5% determines peak area, with reference substance mass concentration (μ g/
Ml) it is abscissa, integrating peak areas value is ordinate, draws standard curve, calculates regression equation, standard curve, coefficient correlation
And the range of linearity, 15 compositions are in good linear relation (R2>0.999)。
The preparation of need testing solution：The ethanol extract and aqueous extract that the embodiment step (2) obtains mix after merging,
Supernatant 1mL is taken, it is standby after 0.45 μm of filtering with microporous membrane.
It is accurate respectively to draw each reference substance solutions of 25 μ L and need testing solution, detected with high performance liquid chromatograph, root
According to testing result, find out each reference substance compound corresponding to peak, record its peak area and calculate compound 1- with calibration curve method
15 content, measurement result are shown in Table 1.
Compound 1-15 content in the tree peony seed extract of 1 embodiment of table 1
Embodiment 2
(1) tree peony seed raw material (1kg) is taken, 10-200 mesh is crushed to, obtains pulvis；
(2) pulvis that step (1) obtains, first with absolute ethyl alcohol seepage pressure effects, ethanol extract (4.32L) is obtained；Water is used again
Seepage pressure effects, obtain aqueous extract (4.32L)；The temperature of seepage pressure effects is room temperature, and the time of seepage pressure effects is 24 hours, diacolation speed
It is 3ml/min to spend for every kilogram of pulvis rate of outflow；
(3) ethanol extract and aqueous extract obtained step (2) concentrates after merging, vacuum drying 24 is small at room temperature
When, obtain tree peony seed extract (102g, hereinafter referred to as extract B).
Analyzed through chromatographic isolation and spectral data, above-mentioned tree peony seed extract still contains compound 1-15, through being repeated several times
Quantitative analysis wherein compound 1-15 content is respectively：
Suffruticosol A (trimerization Stilbene A, 1) content is 0.3%-0.5%, suffruticosol B (trimerization Stilbene B,
2) content is 1.0%-1.2%, trans- ε-viniferin (trans ε-Portugal's root element, 3) content is 1.2%-1.5%,
Ampelopsin E (four poly- Stilbene E, 4) content is that 1.2%-1.5%, trans-resveratrol (trans-resveratrol, 5) contain
Measure as 0.1%-0.3%, trans-resveratrol-4'-O- β-D-glucopyranoside (trans-resveratrol -4'-O-
β-D-Glucose glucoside, 6) content be 0.02%-0.05%, paeoniflorin (Paeoniflorin, 7) content be 0.2%-0.4%,
Luteolin (cyanidenon, 8) content is 0.05%-0.1%, luteolin-4'-O- β-D-glucopyranoside (sweet-scented osmanthus
The plain 4'-O- β-D-Glucose glucoside of grass, 9) content be 0.2%-0.4%, apiolin (10) content be 0.2%-0.3%, Kaempferol
(11) content is 0.2%-0.4%, oleanolic acid (12) content is 0.1%-0.3%, betulic acid (13) content is 0.2%-
0.4%th, hederagenin (14) content be 0.3%-0.5%, caffeic acid (15) content be 0.5%-0.8%.
In 1-2 of the embodiment of the present invention, used peony seeds pick up from Shaanxi Shanglou.
Embodiment 3
Composition A includes active ingredient：suffruticosol A：3mg、suffruticosol B：10mg、trans-ε-
viniferin：12mg、ampelopsin E：12mg、trans-resveratrol：1mg、trans-resveratrol-4'-
O-β-D-glucopyranoside：0.2mg、paeoniflorin：2mg、luteolin：0.5mg、luteolin-4'-O-β-
D-glucopyranoside：2mg, apiolin：2mg, Kaempferol：2mg, oleanolic acid：1mg, betulic acid：2mg, ivy
Sapogenin：3mg, caffeic acid：5mg；Pharmaceutic adjuvant (adds up to selected from microcrystalline cellulose, sodium carboxymethylcellulose, magnesium stearate
Tablet 942.3mg) is made according to common process.
Composition B includes active ingredient：suffruticosol A：5mg、suffruticosol B：12mg、trans-ε-
viniferin：15mg、ampelopsin E：15mg、trans-resveratrol：3mg、trans-resveratrol-4'-
O-β-D-glucopyranoside：0.5mg、paeoniflorin：4mg、luteolin：1mg、luteolin-4'-O-β-D-
glucopyranoside：4mg, apiolin：3mg, Kaempferol：4mg, oleanolic acid：3mg, betulic acid：4mg, ivy soap
Aglycon：5mg, caffeic acid：8mg；Pharmaceutic adjuvant (adding up to 913.5mg selected from starch, sodium carboxymethyl starch, magnesium stearate) is according to normal
Capsule is made in rule technique.
Composition C includes active ingredient：suffruticosol A：3mg、suffruticosol B：10mg、trans-ε-
viniferin：12mg、ampelopsin E：12mg、trans-resveratrol：1mg、trans-resveratrol-4'-
O-β-D-glucopyranoside：0.2mg、paeoniflorin：2mg、luteolin：0.5mg、luteolin-4'-O-β-
D-glucopyranoside：2mg, apiolin：2mg, Kaempferol：2mg, oleanolic acid：1mg, betulic acid：2mg, ivy
Sapogenin：3mg, caffeic acid：2mg；Pharmaceutic adjuvant (adds up to selected from microcrystalline cellulose, sodium carboxymethylcellulose, magnesium stearate
Tablet 945.3mg) is made according to common process.
Composition D includes active ingredient：suffruticosol A：3mg、suffruticosol B：10mg、trans-ε-
viniferin：12mg、ampelopsin E：12mg、trans-resveratrol：1mg、trans-resveratrol-4'-
O-β-D-glucopyranoside：0.2mg、paeoniflorin：2mg、luteolin：0.5mg、luteolin-4'-O-β-
D-glucopyranoside：2mg, apiolin：2mg；Pharmaceutic adjuvant is (selected from microcrystalline cellulose, sodium carboxymethylcellulose, tristearin
Sour magnesium adds up to 955.3mg) tablet is made according to common process.
Extract C：The extract that the method recorded according to embodiment 1 in Chinese patent 201310434769.X is prepared.
Extract D：The extract that the method recorded according to embodiment 2 in Chinese patent 201310434769.X is prepared.
Extract E：The extract that the method recorded according to embodiment 2 in Chinese patent 201310218325.2 is prepared.
Extract F：The extract that the method recorded according to embodiment 3 in Chinese patent 201310218325.2 is prepared.
The tree peony seed extract of embodiment 4, monomer, the antitumor activity of pharmaceutical composition
(1) test material：
2x 10 is made in 5 kinds of tumour cells of selection exponential phase4Individual/mL single cell suspension, it is inoculated in 96 orifice plates
In, in 37 DEG C of constant temperature, 5%CO2Under the conditions of cultivate, be divided into blank group after 24 hours, control group, and medication group handle each cell,
Medication group add 100 μ L sample solution, each concentration be 0.625 μ g/mL, 1.25 μ g/mL, 2.5 μ g/mL, 5 μ g/mL, 25 μ g/mL,
50μg/mL、100μg/mL.Afterwards, continue in CO2Cultivated 24 hours in incubator.After the completion of this process, added to every hole
The 0.5mg/mL μ L of MTT solution 20, continue culture 24 hours.Centrifugation, after removing supernatant, reacted being dissolved in DMSO adding holes
Generation Jia Za, with the OD values at ELIASA detection 570nm, it is repeated 3 times and makes a record.
(2) result
The peony seeds monomeric compound of table 2 and tree peony seed extract of the present invention (embodiment 1, embodiment 2) are to 5 kinds of tumour cells
Inhibitory action
Every group of experiment is repeated 3 times, and is as a result expressed as mean ± SD
It is above-mentioned test result indicates that：(1) pharmaceutical composition provided by the invention and tree peony seed extract are relative to existing
Technology (such as in Chinese patent 201310434769.X embodiment 1-2 prepare peony seed total stilbene compounds as well composition；In
The Paeonia suffruticosa seed shell extract that in state's patent 201310218325.2 prepared by embodiment 2-3；Document Chemical Research
The tree peony seed extract prepared in Chinese Universities, Volume 33, Issue 4, pp 546-551) it is anti-swollen
Tumor activity significantly increases；(2) composition that pharmaceutical composition provided by the invention forms relative to one or several single active ingredients
Antitumor activity significantly increase.
Claims (10)
1. a kind of pharmaceutical composition, it is characterised in that described pharmaceutical composition includes treatment and/or prevention effective dose
Suffruticosol A (trimerization Stilbene A), suffruticosol B (trimerization Stilbene B), trans- ε-viniferin (trans ε-Portugals
Root element), ampelopsin E (four poly- Stilbene E), trans-resveratrol (trans-resveratrol), trans-
Resveratrol-4'-O- β-D-glucopyranoside (trans-resveratrol -4'-O- β-D-Glucose glucoside),
Paeoniflorin (Paeoniflorin), luteolin (cyanidenon), luteolin-4'-O- β-D-glucopyranoside (wood
The plain 4'-O- β-D-Glucose glucoside of rhinoceros grass), apiolin, Kaempferol, oleanolic acid, betulic acid, hederagenin, caffeic acid
As active ingredient.
2. the pharmaceutical composition described in claim 1, it is characterised in that by mass percentage, active ingredient is preferred
Suffruticosol A (trimerization Stilbene A) content is 0.3%-0.5%, suffruticosol B (trimerization Stilbene B) content is
1.0%-1.2%, trans- ε-viniferin (trans ε-Portugal's root element) content are 1.2%-1.5%, ampelopsin E (four
Poly- Stilbene E) content be 1.2%-1.5%, trans-resveratrol (trans-resveratrol) content be 0.1%-0.3%,
Trans-resveratrol-4'-O- β-D-glucopyranoside (trans-resveratrol -4'-O- β-D-Glucose glucoside) contain
It is that 0.2%-0.4%, luteolin (cyanidenon) contain to measure as 0.02%-0.05%, paeoniflorin (Paeoniflorin) content
Measure as 0.05%-0.1%, luteolin-4'-O- β-D-glucopyranoside (cyanidenon 4'-O- β-D-Glucose glucoside)
Content is 0.2%-0.4%, Quantitative Determination of Apigenin 0.2%-0.3%, Kaempferol content are 0.2%-0.4%, oleanolic acid contains
Measure as 0.1%-0.3%, TLC Determination of Betulinic Acid 0.2%-0.4%, hederagenin content are 0.3%-0.5%, coffee
Acid content is 0.5%-0.8%.
3. the pharmaceutical composition described in claim any one of 1-2, it is characterised in that the pharmaceutical composition also includes pharmaceutically may be used
The pharmaceutic adjuvant (such as pharmaceutically acceptable carrier, diluent or excipient) of receiving.
4. a kind of tree peony seed extract, it is characterised in that the preparation method of the tree peony seed extract comprises the following steps：
(1) tree peony seed raw material is taken, crushes, obtains pulvis；
(2) pulvis that step (1) obtains first uses absolute ethyl alcohol seepage pressure effects, obtains ethanol extract；Water seepage pressure effects are used again, obtain water
Extract solution；
(3) ethanol extract and aqueous extract obtained step (2) is concentrated after merging, dried, and obtains the peony seeds extraction
Thing.
5. the tree peony seed extract described in claim 4, it is characterised in that the crushing described in step (1), preferably grinding particle size
For 10-200 mesh, more preferably 40 mesh；The temperature of seepage pressure effects is room temperature in step (2), and the time of seepage pressure effects is 12-
24 hours, diacolation speed was that every kilogram of pulvis rate of outflow is 2~3ml/min；Step (3) described drying is selected from vacuum drying,
Vacuum drying temperature is selected from room temperature to 50 DEG C, vacuum drying time preferred 12-24 hours.
6. the tree peony seed extract described in claim any one of 4-5, it is characterised in that it includes following composition：By quality percentage
Than meter, suffruticosol A (trimerization Stilbene A) content is 0.3%-0.5%, suffruticosol B (trimerization Stilbene B) content is
1.0%-1.2%, trans- ε-viniferin (trans ε-Portugal's root element) content are 1.2%-1.5%, ampelopsin E (four
Poly- Stilbene E) content be 1.2%-1.5%, trans-resveratrol (trans-resveratrol) content be 0.1%-0.3%,
Trans-resveratrol-4'-O- β-D-glucopyranoside (trans-resveratrol -4'-O- β-D-Glucose glucoside) contain
It is that 0.2%-0.4%, luteolin (cyanidenon) contain to measure as 0.02%-0.05%, paeoniflorin (Paeoniflorin) content
Measure as 0.05%-0.1%, luteolin-4'-O- β-D-glucopyranoside (cyanidenon 4'-O- β-D-Glucose glucoside)
Content is 0.2%-0.4%, Quantitative Determination of Apigenin 0.2%-0.3%, Kaempferol content are 0.2%-0.4%, oleanolic acid contains
Measure as 0.1%-0.3%, TLC Determination of Betulinic Acid 0.2%-0.4%, hederagenin content are 0.3%-0.5%, coffee
Acid content is 0.5%-0.8%.
7. the tree peony seed extract described in claim any one of 4-6, it is characterised in that the tree peony seed extract includes as follows
Composition：Suffruticosol A contents are 3.11mg/g, and suffruticosol B contents are 10.73mg/g, trans- ε-
Viniferin contents are 13.16mg/g, and ampelopsin E contents are 12.56mg/g, and trans-resveratrol contents are
2.88mg/g, trans-resveratrol-4'-O- β-D-glucopyranoside contents are 0.74mg/g,
Paeoniflorin contents are 3.33mg/g, and luteolin contents are 0.61mg/g, luteolin-4'-O- β-D-
Glucopyranoside contents are 2.44mg/g, and Quantitative Determination of Apigenin 2.05mg/g, Kaempferol content are 2.92mg/g, Qi Dun
Tartaric acid content is 1.70mg/g, TLC Determination of Betulinic Acid 2.12mg/g, hederagenin content are 3.08mg/g, caffeic acid contains
Measure as 6.18mg/g.
8. the tree peony seed extract described in claim any one of 6-7, it is characterised in that the component content determines through HPLC,
HPLC chromatogram condition is：Column temperature：30℃；Post pressure：19.11MPa；Flow velocity：1mL/min；Wavelength：230nm；Sample size：10μL；Color
Compose post：Synergi 4u Hydro-RP 80R；Column length：250×4.6mm 42μm；Mobile phase A：0.2% phosphate aqueous solution, stream
Dynamic phase B：Acetonitrile；Gradient elution program is：0min：A is 95%, B 5%, 5min：A is 75%, B 25%, 20min：A is
45%, B 55%, 30min：A is 25%, B 75%, 33min：A is 0%, B 100%, 36min：A is that 95%, B is
5%.
9. the preparation method of the tree peony seed extract described in claim any one of 4-6, it is characterised in that comprise the following steps：
(1) tree peony seed raw material is taken, crushes, obtains pulvis；
(2) pulvis that step (1) obtains first uses absolute ethyl alcohol seepage pressure effects, obtains ethanol extract；Water seepage pressure effects are used again, obtain water
Extract solution；
(3) ethanol extract and aqueous extract obtained step (2) is concentrated after merging, dried, and obtains the peony seeds extraction
Thing.Crushing described in step (1), preferably grinding particle size are 10-200 mesh, more preferably 40 mesh；Diacolation in step (2)
The temperature of extraction is room temperature, and time of seepage pressure effects is 12-24 hours, diacolation speed be every kilogram of pulvis rate of outflow be 2~
3ml/min；Step (3) described drying is selected from vacuum drying, and vacuum drying temperature is selected from room temperature to 50 DEG C, and vacuum drying time is excellent
Select 12-24 hours.
10. the pharmaceutical composition or tree peony seed extract described in claim any one of 1-8 are preparing prevention and/or treatment tumour
Application in disease medicament.The preferred colorectal cancer of the tumor disease, colon cancer, liver cancer, stomach cancer, acute promyelocytic leukemic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710658187.8A CN107412221A (en) | 2017-08-03 | 2017-08-03 | A kind of tree peony seed extract and its application as antineoplastic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710658187.8A CN107412221A (en) | 2017-08-03 | 2017-08-03 | A kind of tree peony seed extract and its application as antineoplastic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107412221A true CN107412221A (en) | 2017-12-01 |
Family
ID=60436431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710658187.8A Pending CN107412221A (en) | 2017-08-03 | 2017-08-03 | A kind of tree peony seed extract and its application as antineoplastic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107412221A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108864316A (en) * | 2018-06-08 | 2018-11-23 | 合肥工业大学 | A kind of application in sulfonated tree peony seed polysaccharide and its preparation treatment liver cancer ancillary drug |
| CN110483447A (en) * | 2019-09-09 | 2019-11-22 | 南开大学 | 1 antagonist of Thyroid hormone receptor β and its application |
| CN112830952A (en) * | 2021-03-02 | 2021-05-25 | 湘西自治州奥瑞克医药化工有限责任公司 | Production process for extracting purified oleanolic acid from peony seed meal |
| CN115554340A (en) * | 2022-11-15 | 2023-01-03 | 山东省科学院菏泽分院 | Peony seed meal extract for treating liver cancer in cooperation with chemotherapeutic drugs and preparation method and application thereof |
| CN116036108A (en) * | 2023-01-09 | 2023-05-02 | 天津科技大学 | Traditional Chinese medicine monomer composition for treating, relieving or preventing acute lung injury, method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103272007A (en) * | 2013-06-04 | 2013-09-04 | 中国医学科学院药用植物研究所 | Paeonia plant extract and preparation method and applications thereof |
| CN103494797A (en) * | 2013-09-23 | 2014-01-08 | 河南科技大学 | Composition of peony seed total stilbene compounds as well as extraction method and application thereof |
| CN106265977A (en) * | 2015-06-04 | 2017-01-04 | 伽蓝（集团）股份有限公司 | Seed of Flos Moutan extract and preparation method and application, include its skin preparations for extenal use |
-
2017
- 2017-08-03 CN CN201710658187.8A patent/CN107412221A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103272007A (en) * | 2013-06-04 | 2013-09-04 | 中国医学科学院药用植物研究所 | Paeonia plant extract and preparation method and applications thereof |
| CN103494797A (en) * | 2013-09-23 | 2014-01-08 | 河南科技大学 | Composition of peony seed total stilbene compounds as well as extraction method and application thereof |
| CN106265977A (en) * | 2015-06-04 | 2017-01-04 | 伽蓝（集团）股份有限公司 | Seed of Flos Moutan extract and preparation method and application, include its skin preparations for extenal use |
Non-Patent Citations (4)
| Title |
|---|
| CHUN-NIAN HE等: "Three New Oligostilbenes from the Seeds of Paeonia suffruticosa", 《CHEM. PHARM. BULL.》 * |
| NADIN MARWAN ALMOSNID等: "In vitro antitumor effects of two novel oligostilbenes, cis- and trans-suffruticosol D, isolated from Paeonia suffruticosa seeds", 《INTERNATIONAL JOURNAL OF ONCOLOGY》 * |
| TIAN XIAO等: "Quantitative Analysis and Chemical Fingerprint Similarity for Quality Control of the Seeds of Paeonia suffruticosa Andr. by HPLC", 《CHEM. RES. CHIN. UNIV.》 * |
| 易军鹏等: "牡丹籽的化学成分研究", 《天然产物研究与开发》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108864316A (en) * | 2018-06-08 | 2018-11-23 | 合肥工业大学 | A kind of application in sulfonated tree peony seed polysaccharide and its preparation treatment liver cancer ancillary drug |
| CN108864316B (en) * | 2018-06-08 | 2020-11-24 | 合肥工业大学 | Sulfonated peony seed polysaccharide and application thereof in preparation of auxiliary medicine for treating liver cancer |
| CN110483447A (en) * | 2019-09-09 | 2019-11-22 | 南开大学 | 1 antagonist of Thyroid hormone receptor β and its application |
| CN112830952A (en) * | 2021-03-02 | 2021-05-25 | 湘西自治州奥瑞克医药化工有限责任公司 | Production process for extracting purified oleanolic acid from peony seed meal |
| CN115554340A (en) * | 2022-11-15 | 2023-01-03 | 山东省科学院菏泽分院 | Peony seed meal extract for treating liver cancer in cooperation with chemotherapeutic drugs and preparation method and application thereof |
| CN116036108A (en) * | 2023-01-09 | 2023-05-02 | 天津科技大学 | Traditional Chinese medicine monomer composition for treating, relieving or preventing acute lung injury, method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107412221A (en) | A kind of tree peony seed extract and its application as antineoplastic | |
| Fecka et al. | Determination of water-soluble polyphenolic compounds in commercial herbal teas from Lamiaceae: peppermint, melissa, and sage | |
| EP1800685B1 (en) | Steroidal saponin pharmaceutical composition, its preparation method and use | |
| CN106946766B (en) | Alkaloid compound and its extraction separation method in purslane | |
| CN103342687B (en) | Compounds with tyrosinase inhibitory activity and preparation and application thereof | |
| KR20170125744A (en) | Manufacturing method of high quality red platycodon and red platycodon thereof | |
| Hu et al. | Efficacy evaluation of a Chinese bitter tea (Ilex latifolia Thunb.) via analyses of its main components | |
| Xu et al. | Flavonoids from the capitula of Eriocaulon australe | |
| Qiu et al. | Kaempferol separated from Camellia oleifera meal by high-speed countercurrent chromatography for antibacterial application | |
| KR101209574B1 (en) | Pharmaceutical compositions and health functional foods compositions for the improvement of liver functions containing compound isolated from Youngia denticulata as an active ingredient | |
| KR102343912B1 (en) | Composition for anti-cancer or anti-inflammation comprising complex ionized mineral solution as effective component | |
| Welch | Chemistry and pharmacology of Kinkéliba (Combretum micranthum), a West African medicinal plant | |
| CN105640971B (en) | Application of the total saposins in terms of preparing auxiliary hyperglycemic drug in prematurity Fructus Monordicae extract | |
| Shibano et al. | Determination of flavonoids in licorice using acid hydrolysis and reversed-phase HPLC and evaluation of the chemical quality of cultivated licorice | |
| Zhang et al. | A systematical review on ethnobotanical, phytochemical and pharmacological aspects of Dendrobium nobile Lindl. | |
| CN103497091B (en) | Compound with tyrosinase inhibitory activity and preparation method thereof | |
| CN101732377B (en) | Method for preparing anti-cancer total saponin extracts of oplopanax elatus nakai leaves | |
| CN107629104A (en) | Triterpenoid saponin medical compounds and its preparation and application | |
| CN103739660B (en) | A kind of compound, its extracting method, its application preparing antitumor drug and antitumor drug of preparation thereof | |
| KR101911003B1 (en) | Ultrasonic extract of Lespedeza cuneate and method for extracting the same | |
| KR20170138307A (en) | Ultrasonic extract of Lespedeza cuneate and method for extracting the same | |
| CN103739657B (en) | A kind of Sasanguasaponin compound, its preparation method, the antitumor drug applying and prepare | |
| CN103665090B (en) | Ilex cornuta saponin compound, its preparation method and application | |
| CN108530505A (en) | A kind of flavonoid glycoside compound and its preparation method and application | |
| CN100509831C (en) | Wheat bran flavonoid compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171201 |
|
| RJ01 | Rejection of invention patent application after publication |